Literature DB >> 33730436

Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life.

Joseph M Collaco1, Sharon A McGrath-Morrow2.   

Abstract

Respiratory disease is unfortunately common in preterm infants with the archetype being bronchopulmonary dysplasia (BPD). BPD affects approximately 50,000 preterm infants in the U.S. annually with substantial morbidity and mortality related to its pathology (alveolar, airway, and pulmonary vasculature maldevelopment). Predicting the likelihood and severity of chronic respiratory disease in these children as they age is difficult and compounded by the lack of consistent phenotyping. Barriers to understanding the actual scope of this problem include few longitudinal studies, information limited by small retrospective studies and the ever-changing landscape of therapies in the NICU that affect long-term respiratory outcomes. Thus, the true burden of adult respiratory disease caused by premature birth is currently unknown. Nevertheless, limited data suggest that a substantial percentage of children with a history of BPD have long-term respiratory symptoms and persistent airflow obstruction associated with altered lung function trajectories into adult life. Small airway disease with variable bronchodilator responsiveness, is the most common manifestation of lung dysfunction in adults with a history of BPD. The etiology of this is unclear however, developmental dysanapsis may underlie the airflow obstruction in some adults with a history of BPD. This type of flow limitation resembles that of aging adults with chronic obstructive lung disease with no history of smoking. It is also unclear whether lung function abnormalities in people with a history of BPD are static or if these individuals with BPD have a more accelerated decline in lung function as they age compared to controls. While some of the more significant mediators of lung function, such as tobacco smoke and respiratory infections have been identified, more work is necessary to identify the best means of preserving lung function for individuals born prematurely throughout their lifespan.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  adult lung function; bronchopulmonary dysplasia; dysanapsis

Mesh:

Year:  2021        PMID: 33730436      PMCID: PMC8446084          DOI: 10.1002/ppul.25301

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  93 in total

1.  Newborn DNA-methylation, childhood lung function, and the risks of asthma and COPD across the life course.

Authors:  Herman T den Dekker; Kimberley Burrows; Janine F Felix; Lucas A Salas; Ivana Nedeljkovic; Jin Yao; Sheryl L Rifas-Shiman; Carlos Ruiz-Arenas; N Amin; Mariona Bustamante; Dawn L DeMeo; A John Henderson; Caitlin G Howe; Marie-France Hivert; M Arfan Ikram; Johan C de Jongste; Lies Lahousse; Pooja R Mandaviya; Joyce B van Meurs; Mariona Pinart; Gemma C Sharp; Lisette Stolk; André G Uitterlinden; Josep M Anto; Augusto A Litonjua; Carrie V Breton; Guy G Brusselle; Jordi Sunyer; George Davey Smith; Caroline L Relton; Vincent W V Jaddoe; Liesbeth Duijts
Journal:  Eur Respir J       Date:  2019-04-04       Impact factor: 16.671

2.  Dysanaptic lung growth: an experimental and allometric approach.

Authors:  J P Mortola
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-05

Review 3.  Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More.

Authors:  Joseph M Collaco; Sharon A McGrath-Morrow
Journal:  Ann Am Thorac Soc       Date:  2018-05

4.  Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.

Authors:  Steven H Abman; Joseph M Collaco; Edward G Shepherd; Martin Keszler; Milenka Cuevas-Guaman; Stephen E Welty; William E Truog; Sharon A McGrath-Morrow; Paul E Moore; Lawrence M Rhein; Haresh Kirpalani; Huayan Zhang; Linda L Gratny; Susan K Lynch; Jennifer Curtiss; Barbara S Stonestreet; Robin L McKinney; Kevin C Dysart; Jason Gien; Christopher D Baker; Pamela K Donohue; Eric Austin; Candice Fike; Leif D Nelin
Journal:  J Pediatr       Date:  2016-11-28       Impact factor: 4.406

5.  Predictive value of infant lung function testing for airway malacia.

Authors:  Els C van der Wiel; Ward Hofhuis; Wim P J Holland; Harm A W M Tiddens; Johan C de Jongste; Peter J F M Merkus
Journal:  Pediatr Pulmonol       Date:  2005-11

Review 6.  Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis.

Authors:  Eric S Shinwell; Igor Portnov; Joerg J Meerpohl; Tanja Karen; Dirk Bassler
Journal:  Pediatrics       Date:  2016-12       Impact factor: 7.124

7.  Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.

Authors:  H Valkonen; M Waris; A Ruohola; O Ruuskanen; T Heikkinen
Journal:  Allergy       Date:  2009-03-23       Impact factor: 13.146

8.  Indoor Air Pollution Sources and Respiratory Symptoms in Bronchopulmonary Dysplasia.

Authors:  Jessica L Rice; Sharon A McGrath-Morrow; Joseph M Collaco
Journal:  J Pediatr       Date:  2020-05-13       Impact factor: 4.406

Review 9.  Neutrophilic Inflammation in the Pathogenesis of Chronic Obstructive Pulmonary Disease.

Authors:  Aidan Butler; Georgia May Walton; Elizabeth Sapey
Journal:  COPD       Date:  2018-07-31       Impact factor: 2.409

Review 10.  Tracheostomy in childhood: review of the literature on complications and mortality over the last three decades.

Authors:  Ana Paula Ligoski Dal'Astra; Ariane Vieira Quirino; Juliana Alves de Sousa Caixêta; Melissa Ameloti Gomes Avelino
Journal:  Braz J Otorhinolaryngol       Date:  2016-05-06
View more
  2 in total

1.  Area deprivation and respiratory morbidities in children with bronchopulmonary dysplasia.

Authors:  Emma Banwell; Joseph M Collaco; Gabriela R Oates; Jessica L Rice; Lucia D Juarez; Lisa R Young; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2022-05-21

Review 2.  Influences of environmental exposures on preterm lung disease.

Authors:  Joseph M Collaco; Brianna C Aoyama; Jessica L Rice; Sharon A McGrath-Morrow
Journal:  Expert Rev Respir Med       Date:  2021-06-17       Impact factor: 3.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.